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Oestrogen is known to influence blood lipid levels and though its cardioprotective effects are less clear than once thought, there
remains concern that reduction of oestrogen levels during hormonal treatment for breast cancer may have an adverse effect on
cardiovascular risk. While tamoxifen has been shown to improve lipid profiles, the aromatase inhibitors have a very different mode of
action and do not possess the oestrogen-agonistic effects of tamoxifen. At present, there are few data on the effects of these agents
on lipid profiles. Available data are mixed, but suggest that the different aromatase inhibitors have different effects on lipid profiles.
Some studies show anastrozole as generally having little effect on lipids, while others have indicated adverse effects on lipid profiles/
increased hypercholesterolaemia. Letrozole has been associated with adverse effects on lipid profiles in some studies, including BIG 1-
98, but short-term data from randomised trials do not show increased cardiovascular morbidity. By contrast, exemestane, which has
been studied in slightly more detail, may either have little effect or may be associated with slightly improved lipid profiles. In general,
the changes have been small and are likely to be of little relevance in women with advanced breast cancer, but if these agents come
to be used in early breast cancer, their impact on lipid profiles may become more important. Many studies are currently underway
with the aromatase inhibitors, with safety assessments including monitoring lipid levels. The results of these studies are keenly awaited.
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Clinical evidence points to low-density lipoprotein (LDL) choles-
terol as the key factor in the pathogenesis of atherosclerosis and
coronary heart disease (CHD), while high-density lipoprotein
(HDL) cholesterol appears to have a protective effect. Increases in
LDL cholesterol are associated with increased risk for CHD, even
when total cholesterol concentration is within the normal range.
Women generally appear to have higher levels of HDL cholesterol
than men. Furthermore, some studies have suggested that
low levels of HDL cholesterol, particularly high total/HDL ratio or
low HDL2 subfraction, could be a more significant risk factor for
women than men, with total cholesterol being less important for
women (Kannel, 1987; Miller-Bass et al, 1993). The role of
triglycerides is controversial, but elevated triglycerides have been
suggested to be a stronger predictor of cardiovascular diseases in
women than in men (Korhonen et al, 1996; La Rosa, 1997). Finally,
high lipoprotein (a) (Lp(a)) levels have been associated with an
increased risk both in women and men (Danesh et al, 2000).
Oestrogen is known to affect blood lipids, with levels of HDL
cholesterol increasing and LDL cholesterol decreasing with rising
levels of oestrogen. Reduced oestrogen levels, such as occurs at
menopause, has been found to cause atherogenic alterations in
lipid and lipoprotein profiles in epidemiological studies comparing
premenopausal women with menopausal and postmenopausal
women (Schaefer et al, 1994; de Aloysio et al, 1999; Tremollieres
et al, 1999), and also in longitudinal trials (Do et al, 2000).
Increases in both total and LDL cholesterol concentrations are seen
during menopause. Additionally, a shift to smaller, denser and
potentially more atherogenic LDL particle sizes has been noted
(Campos et al, 1988). Data on HDL cholesterol have been
inconsistent, as HDL cholesterol has been reported to remain
unaffected in some studies (Kannel, 1987), while others have noted
a decline of HDL cholesterol, particularly HDL2 subfraction, with a
rise of HDL3 cholesterol, which may result in an unfavourable net
effect (Matthews et al, 1994). Increases in plasma triglycerides and
Lp(a) concentrations have also been reported after menopause
(Stevenson et al, 1993).
However, there has been controversy about the importance
of endogenous oestrogens to cardiovascular risk, because age and
menopause are closely related and lipid profiles change with age.
In fact, the influence of menopause on lipoprotein changes varies
between different studies (Stevenson et al, 1993), and its influence
has been suggested to be lower when age and other confounding
factors are taken into account (Matthews et al, 1994; de Aloysio
et al, 1999).
For many years it was accepted that hormone replacement
therapy with oestrogen could partly reverse the increase in
cardiovascular risk occurring at menopause. However, the
cardioprotective effects of exogenous oestrogen have now been
called into question (Hulley et al, 1998; Women’s Health Initiative
Steering Committee, 2004). Despite doubts surrounding the effects
of oestrogen on cardiovascular risk, there remains concern that
lowering oestrogen levels during adjuvant therapy for breast
cancer might have detrimental effects on lipid levels and might
also increase cardiovascular risk. This is particularly relevant given
that the greatest cause of death in women with early stage breast
cancer is heart disease (Levi et al, 2002). Although tamoxifen has
not been shown to increase the risk of cardiovascular disease, it
has a very different mode of action from the aromatase inhibitors,
which are increasingly being used in the adjuvant setting. This
has triggered considerable interest in the lipid effects of these
agents.
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LIPID PROFILES
Tamoxifen
Tamoxifen has oestrogenic agonist effects on blood lipids, with
several studies describing small changes in plasma lipoprotein
concentrations, most of the changes potentially reducing the
risk of cardiovascular disease (Dziewulska-Bokiniec et al, 1994;
Thangaraju et al, 1994; Love et al, 1994; Grey et al, 1995; Decensi
et al, 1998; Vrbanec et al, 1998; Cushman et al, 2001). Total and
LDL cholesterol levels are decreased (Grey et al, 1995) and there is
a tendency for HDL cholesterol levels to be increased, although this
is often marginal (Thangaraju et al, 1994; Love et al, 1994; Decensi
et al, 1998; Vrbanec et al, 1998). Tamoxifen has also been shown
to lower Lp(a) levels (Decensi et al, 1998). Triglyceride levels appear
to increase (Dziewulska-Bokiniec et al, 1994; Grey et al, 1995).
Levels of apolipoprotein B-100 and apolipoprotein A-I are also
reduced with tamoxifen (Elisaf et al, 1996). These effects are
thought to be caused by the ability of tamoxifen to act as a partial
agonist in some tissues. By contrast, the aromatase inhibitors do
not have oestrogenic effects, which has led to concern about
possible detrimental effects to lipid profiles.
Aromatase inhibitors
To date, few studies have been conducted that include an
assessment of lipid effects, and conflicting results have been
obtained from those that have. The different aromatase inhibitors
appear to have different effects on lipid profiles (Table 1). This
may be a result of their different modes of action. Anastrozole and
letrozole are nonsteroidal aromatase inhibitors, while exemestane
is a steroidal aromatase inhibitor. The steroidal inhibitors are
analogues of androstenedione and bind to the same site on the
aromatase molecule, but unlike androstenedione they bind
irreversibly, because of their conversion to reactive intermediates
by aromatase. The nonsteroidal agents, by contrast, bind reversibly
to the heme group of the enzyme.
Anastrozole In several small studies, anastrozole showed no
marked effects on lipid profile (Dewar et al, 2000; Kataja et al,
2002; Sawada and Sato, 2003; Wojtacki et al, 2004). Kataja et al,
(2002) showed LDL levels fell with both exemestane and
anastrozole and triglycerides fell with exemestane, but remained
stable with anastrozole. However, anastrozole was associated with
a higher incidence of hypercholesterolaemia than tamoxifen in
the ATAC study (ATAC Trialists Group, 2002). In the Italian
Tamoxifen Arimidex (ITA) trial, patients switching to anastrozole
after 2 or more years of tamoxifen were also found to have higher
levels of hypercholesterolaemia than those continuing on tamoxifen,
8.1 and 2.7%, respectively (Boccardo et al, 2003). In addition, a
recent study of the effect of anastrozole on serum lipid profiles in
38 postmenopausal patients with breast cancer found significant
increases in total cholesterol, LDL and HDL cholesterol, apolipo-
protein A1, B and lp(a) (Hozumi et al, 2004). Anastrozole was
associated with a slightly higher incidence of ischaemic cardio-
vascular disease than tamoxifen in the ATAC study, but this was
not significant (ATAC Trialists Group, 2002).
Letrozole Increases in total serum cholesterol, LDL cholesterol,
apo B and serum-lipid risk ratios for cardiovascular disease were
found in some studies (Nicolaides et al, 2000; Elisaf et al, 2001),
while others have found no changes in lipid profile (Harper-
Wynne et al, 2001). In the first interim analysis of a 5-year study of
letrozole therapy after the completion of 5 years’ tamoxifen
treatment, Goss et al (2003) found no significant differences in the
rates of cardiovascular events between the letrozole group (4.1%)
and the placebo group (3.6%), and there were no reports of drug-
related hypercholesterolaemia. By contrast, the first results of the
BIG 1-98 trial comparing letrozole with tamoxifen have shown
that 43.6% of letrozole-treated patients developed mild to
moderate hypercholesterolaemia vs 18.2% of tamoxifen-treated
patients (Thurlimann, 2005). While more tamoxifen-treated
patients suffered thromboembolic events than letrozole patients
(grades 3–5, 2 vs 0.8%), a higher incidence of cardiovascular events
was seen with letrozole-treated patients than tamoxifen patients
(grades 3–5, 3.6 vs 2.5%), although this was not significant.
Longer-term follow-up will be required to establish the signifi-
cance of hypercholesterolaemia seen in the BIG 1–98 trial
(Thurlimann, 2005).
Exemestane The lipid effects of exemestane have, perhaps, been
more closely studied than those of the other aromatase inhibitors.
In animal studies, exemestane reversed the increase in LDL
cholesterol and total cholesterol seen in ovariectomized cycling
Sprague–Dawley rats (Goss et al, 2001).
In a 3-month study compared with anastrozole and tamoxifen
in postmenopausal women with breast cancer (n¼30), exemestane
produced a small decrease in serum cholesterol and LDL
cholesterol, decreases in triglycerides and HDL cholesterol (Kataja
et al, 2002). In the same study, anastrozole showed similar results
except for a small increase in HDL cholesterol (Kataja et al, 2002).
The EORTC trial 10951 randomized 382 postmenopausal breast
cancer patients to exemestane or tamoxifen once daily as first-line
treatment in the metastatic setting (Atalay et al, 2004; Paridaens
et al, 2004). A companion substudy to this trial analysing effects on
lipid profiles revealed no adverse effects on total cholesterol, HDL
cholesterol, apolipoprotein A1 and B or Lp(a) levels at 8, 24 and 48
weeks of treatment with either exemestane or tamoxifen (72
patients included in the statistical analysis) (Atalay et al, 2004).
By contrast, exemestane decreased but tamoxifen increased tri-
glyceride levels. In the Greek substudy of the TEAM trial, which is
comparing tamoxifen with exemestane as initial therapy, baseline
lipid levels have been compared with levels at 3 and 6 months of
treatment in 37 patients. At 6 months, exemestane appeared to
stabilize total cholesterol and HDL cholesterol levels as did
tamoxifen (Markopoulos et al, 2003). Exemestane had a non-
significant trend to increase LDL cholesterol levels at 3 and 6
months, but reduced triglyceride levels at both time points and
Table 1 Effects of anti-oestrogen therapy on plasma lipid levels (Dewar et al, 2000; Nicolaides et al, 2000; Elisaf et al, 2001; Goss et al, 2001, 2003;
Harper-Wynne et al, 2001; ATAC, 2002; Kataja et al, 2002; Boccardo et al, 2003; Markopoulos et al, 2003; Sawada and Sato, 2003; Atalay et al, 2004;
Coombes et al, 2004; Hozumi et al, 2004; Paridaens et al, 2004; Wojtacki et al, 2004)
LDL cholesterol HDL cholesterol Total cholesterol Triglycerides Total:HDL cholesterol Lp(a) Apo B
Tamoxifen k   k ?? kk
Anastrozole m  m/  m/     m/  m/ 
Letrozole m/   m/   m/  ? m/ 
Exemestane k  k/  k/  k ?   
Key: m¼increased; k¼decreased;  ¼no change; ?¼unknown.
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although cholesterol levels were not systematically measured in the
recent IES study comparing exemestane with tamoxifen in 4742
women, it was noted that there was no significant difference in
the incidence of myocardial infarction between the two groups
(Coombes et al, 2004).
With regard to postmenopausal patients with early breast
cancer, results were reported at the 2004 ASCO meeting of the
effects of exemestane, 25mgday
 1, vs placebo on lipid and
coagulation profiles (Krag et al, 2004). After 2 years, lipid profiles
were similar for exemestane and placebo with decreased levels of
cholesterol, LDL cholesterol, triglycerides, apolipoprotein A1 and
B and Lp(a) seen in both groups. The only difference was a small
decrease in HDL cholesterol seen with exemestane only (Krag et al,
2004).
CLINICAL SIGNIFICANCE OF LIPID EFFECTS
The significance of changes in lipid profiles seen with different
aromatase inhibitors is impossible to assess from the limited data
available. The changes seen are generally small. For example, in the
study by Elisaf et al, (2001), mean LDL cholesterol levels increased
from 148750 to 170753mgdl
 1 after 16 weeks with letrozole,
while the total cholesterol to HDL cholesterol ratio increased from
3.9471.46 to 4.4871.40 after 16 weeks. Such a change might be
sufficient to alter a patient’s risk category from low to moderate
depending on other risk factors, therefore triggering the need for
lipid-lowering treatment.
The benefits of receiving an aromatase inhibitor are likely to
outweigh the disadvantages of any changes to lipid profiles,
particularly for patients with advanced disease. However, when
aromatase inhibitors are used in early disease or in the prevention
setting, an increase of 10–15% in circulating cholesterol and
triglycerides may have a significant impact on the risk of
cardiovascular disease, and monitoring of blood lipid levels and
instigation of lipid lowering treatment if required should be
undertaken. In such instances, the choice of agent may be
particularly important in the adjuvant and prevention settings,
and agents that have minimal effects on lipids will be preferred,
especially if evidence of reduced cardiovascular morbidity can be
demonstrated in clinical trials.
EFFECTS OF ANTI-OESTROGEN TREATMENT ON
STROKE AND THROMBOEMBOLISM
Tamoxifen increases the risk of venous thromboembolism, but it
has been unclear as to the implications of this for risk of stroke.
However, a recently published meta-analysis of tamoxifen breast
cancer trials revealed an increased risk of stroke with tamoxifen
compared with placebo/control (Bushnell and Goldstein, 2004).
Results of the meta-analysis showed tamoxifen-treated patients
had an 82% and a 29% increased risk of ischaemic stroke and
any stroke, respectively, although the authors noted that the
absolute risk was small (Bushnell and Goldstein, 2004). The
notable increased risk in ischaemic stroke was suggested to be a
consequence of the tamoxifen-associated increase in thrombosis.
Further studies with tamoxifen to include measurements of
prespecified cerebrovascular outcomes will help to clarify the
stroke risk with tamoxifen; meanwhile, tamoxifen may be best
avoided for women with a history of stroke or thrombosis.
The risk of cerebrovascular and thromboembolic events has
been seen to be significantly higher with tamoxifen than the
aromatase inhibitors; for example, anastrozole was associated with
significantly fewer ischaemic cerebrovascular events (P¼0.0006)
and thromboembolic events (P¼0.0006) than tamoxifen in the
ATAC trial (ATAC Trialists Group, 2002). Results of the IES
study also showed thromboembolic events as more frequent with
tamoxifen than exemestane (P¼0.007) (Coombes et al, 2004). In
addition, no thromboembolic events were observed with letrozole
at a dose of 2.5mg in a study compared with megestrol acetate
for advanced breast cancer (Table 2) (Dombernowsky et al, 1998).
Since the aromatase inhibitors are not usually associated with
thrombosis, women with a previous history of thrombosis or
stroke should receive an aromatase inhibitor in preference to
tamoxifen.
ONGOING AND PLANNED CLINICAL TRIALS
Clearly, more data are needed before the relevance of the changes
in lipid levels with aromatase inhibitors on cardiovascular
morbidity can be determined. Indeed, most of the ongoing clinical
trials are including analysis of lipid effects as part of their protocol.
However, care needs to be taken when evaluating lipid effects in
studies comparing aromatase inhibitors with tamoxifen, because
tamoxifen itself influences lipid values.
Among the ongoing trials that will report on lipid changes are:
  MA17L: is a substudy of the MA17 study involving 300 patients
randomised to letrozole or placebo after completing 5 years with
tamoxifen.
  BIG FEMTA(1-98): is comparing 5 years of tamoxifen, 5 years of
letrozole or sequenced therapy of 2–3 years each starting with
either tamoxifen or letrozole.
  NSABP B33: is a randomised, placebo-controlled, double-blind
trial evaluating the effect of exemestane in 3000 clinical stage
T1-3 N0-1 M0 postmenopausal breast cancer patients completing
at least 5 years of tamoxifen therapy.
  TEAM: preliminary lipid results have already been reported
from this phase III randomised study of adjuvant exemestane vs
adjuvant tamoxifen in 4400 postmenopausal women with early
breast cancer (Markopoulos et al, 2003). Final results are
awaited.
  ARNO: in this study, women receive 2 years of tamoxifen
followed by randomisation to 3 years of either anastrozole or
tamoxifen.
Table 2 Incidence of thromboembolic events with aromatase inhibitors and comparators
Thromboembolic events (% of patients)
Reference Aromatase inhibitor Comparator P-value
ATAC (2002) Anastrozole 64 (2.1%) Tamoxifen 109 (3.5%) ¼0.0006
Coombes et al (2004) (IES Trial) Exemestane 30 (1.3%) Tamoxifen 55 (2.4%) ¼0.007
Dombernowsky et al (1998) Letrozole (2.5mg) 1 (0%) Megestrol acetate 15 (7.9%) Unknown
Letrozole (0.5mg) 2 (1%)
Goss et al (2003) (MA-17 trial) (cardiovascular events) Letrozole (2.5mg) 88 (4.1%) Placebo 77 (3.6%) ¼0.4
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followed by 2 years of either tamoxifen or exemestane.
  IMPACT: compares anastrozole vs tamoxifen alone and
in combination as neoadjuvant treatment of oestrogen receptor
positive operable breast cancer in postmenopausal women.
  NCIC CTG MAP2: is a randomised study of the effect of
exemestane vs placebo on breast density in postmeno-
pausal women at increased risk for development of breast
cancer.
CONCLUSIONS
Concern about lipid changes associated with aromatase inhibitors
leading to increased cardiovascular deaths has not so far been
borne out in the limited data from adjuvant trials. Of the available
data on effects of aromatase inhibitors on serum lipids from short-
term studies, exemestane has little or possibly a slight beneficial effect
on serum lipids, and anastrozole appears to have little effect or possibly
an adverse effect, while letrozole may have a detrimental effect.
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